贝伐珠单抗联合紫杉醇加顺铂化疗方案对晚期非鳞状细胞型非小细胞肺癌患者肿瘤标志物及生存情况的影响  

Effect of Bevacizumab Combined with Paclitaxel and Cisplatin Chemotherapy Regimen on Tumor Markers and Survival in Patients with Advanced Non-Squamous Cell Non-Small Cell Lung Cancer

作　　者：唐敏 TANG Min(Department of NO.2 Oncology,Guiyang Public Health Clinical Center,Guiyang 550000,China)

机构地区：[1]贵州省贵阳市公共卫生救治中心肿瘤二科,贵州贵阳550000

出　　处：《中国伤残医学》2025年第4期71-74,84,共5页Chinese Journal of Trauma and Disability Medicine

摘　　要：目的:探讨贝伐珠单抗联合紫杉醇加顺铂化疗方案对晚期非鳞状细胞型非小细胞肺癌(NSCLC)患者肿瘤指标及生存情况的影响。方法:选取2021年5月-2022年5月贵阳市公共卫生救治中心收治的74例晚期非鳞状细胞型NSCLC患者为研究对象,采用随机数字表法将其分为对照组及研究组,各37例。对照组采用常规的紫杉醇联合顺铂(TP)化疗方案治疗,研究组在对照组基础上采用贝伐珠单抗治疗。比较两组临床疗效、肿瘤标志物水平、生存情况及不良反应发生情况。结果:治疗3个周期后,研究组临床控制率为89.19%,高于对照组67.57%,治疗整体效果优于对照组,差异均有统计学意义(P<0.05)。治疗3个周期后,研究组的血管内皮生长因子、糖类抗原125、癌胚抗原水平均低于对照组,差异均有统计学意义(P<0.05)。研究组2年内死亡患者的无进展生存期、总生存期均长于对照组,差异均有统计学意义(P<0.05);研究组的1年生存率、2年生存率分别为81.08%、56.76%,与对照组的64.86%、40.54%比较,差异均无统计学意义(P>0.05)。研究组的胃肠道反应、白细胞计数降低、血小板计数降低发生率分别为16.22%、8.11%、10.81%,均低于对照组的37.84%、27.03%、32.43%,差异均有统计学意义(P<0.05);研究组的肝功能异常发生率为8.11%,与对照组的24.32%比较,差异无统计学意义(P>0.05)。结论:贝伐珠单抗联合紫杉醇加顺铂化疗方案可显著提高晚期非鳞癌NSCLC患者的临床控制率,降低其肿瘤标志物水平,延长无进展生存期和总生存期。Objective:To investigate the effects of Bevacizumab combined with Paclitaxel and Cisplatin chemotherapy regimen on tumor makers and survival in patients with advanced non-squamous cell non-small cell lung cancer(NSCLC).Methods:A total of 74 patients with advanced non-squamous cell NSCLC treated in Guiyang Public Health Clinical Center from May 2021 to May 2022 were selected as the study objects,and were divided into a control group and a study group by random number table method,with 37 cases in each group.The control group was treated with conventional Paclitaxel combined with Cisplatin(TP)chemotherapy regimen,and the study group was treated with Bevacizumab on the basis of the control group.The clinical efficacy,tumor marker levels,survival situation and adverse reaction were compared between the two groups.Results:After 3 cycles of treatment,the clinical control rate of the study group was 89.19%,which was higher than 67.57% of the control group,the overall effect of treatment was better than that of control group,the difference were statistically significant(P<0.05).After 3 cycles of treatment,the levels of vascular endothelial growth factor,carbohydrate antigen 125 and carcinoembryonic antigen in the study group were lower than those in the control group,the differences were statistically significant(P<0.05).The progression-free survival and overall survival of patients who died within 2 years in the study group were longer than those in the control group,the differences were statistically significant(P<0.05);the 1-year survival rate and 2-year survival rate of the study group were 81.08% and 56.76%,respectively,compared with 64.86% and 40.54% of the control group,there were no significant differences(P>0.05).The incidence of gastrointestinal reaction,decreased white blood cell count and decreased blood platelet count in the study group were 16.22%,8.11% and 10.81%,respectively,which were lower than 37.84%,27.03% and 32.43% in the control group,with statistical significance(P<0.05);the incidence of abnormal

关 键 词：非小细胞肺癌 晚期 贝伐珠单抗 紫杉醇 顺铂 肿瘤标志物 

分 类 号：R734.2[医药卫生—肿瘤]